Instance we were unable to analyze publication bias using funnel plots
Instance we were unable to analyze publication bias using funnel plots, since it is known that at least ten RCTs are required to get statistically significant results [18]. A concept that must be born in mind when using corifollitropin alfa is that its unique pharmacokinetic profile can result in the recruitment of an increased cohort of developing follicles, and this contraindicates itsFensore et al. Journal of Ovarian Research (2015) 8:Page 8 ofuse in high responder patients that are at risk of OHSS. Adequate definition of the ovarian reserve and thus exclusion of patients with high ovarian reserve appears to remain a crucial step before considering long lasting FSH for COS.7.8.Conclusions Corifollitropin alfa was designed to simplify the treatment regimen in patients undergoing ovarian stimulation for IVF. This systematic review and meta-analysis suggests that corifollitropin alfa is effective as rFSH in terms of live birth rate, ongoing pregnancy rate and clinical pregnancy rate. The increased number of eggs retrieved under corifollitropin alfa regimen reflects the elevated effectiveness of this novel FSH formulation, but warns at the same time PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28192408 Sinensetin site against the possible increased risk of OHSS in high responder women.Abbreviations CI: Confidence interval; COS: Controlled ovarian stimulation; ICSI: Intracytoplasmic sperm injection; IVF: In vitro fertilization; OHSS: Ovarian hyperstimulation syndrome; OR: Odds ratios; rFSH: Recombinant follicle stimulating hormone; RTCs: Randomized controlled trials; WMD: Weighted mean differences. Competing interests The authors declare that they have no competing interests. Authors’ contributions All the authors contributed towards the construction of the study. SF and GMT performed the search and collected data. SF and MDM performed statistical analyses. All authors contributed to manuscript drafting and critical discussion of the manuscript. All authors read and approved the manuscript. Acknowledgment Supported by internal funds. Author details 1 Unit?di Statistica, Dipartimento di Scienze Filosofiche, Pedagogiche ed Economico-Quantitative, University “G. d’Annunzio” of Chieti-Pescara, Pescara, Italy. 2Dipartimento di Medicina e Scienze dell’Invecchiamento, University “G. d’Annunzio” of Chieti-Pescara, Chieti, Italy. Received: 20 January 2015 Accepted: 21 May9.10.11.12.13.14.15.16.17.18.de Greef R, Zandvliet AS, de Haan AF, Ijzerman-Boon PC, MarintchevaPetrova M, Mannaerts BM. Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clin Pharmacol Ther. 2010;88:79?7. Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod. 2002;17:1987?3. Corifollitropin Alfa Dose-finding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod. 2008;23:2484?2. Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst Rev. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26577270 2012 Jun. doi:10.1002/14651858.CD009577 Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertil Steril. 2012;97:876?5. De.
